Alvine Pharmaceuticals commences Stage 2a clinical trial to evaluate the efficacy of ALV003 Alvine Pharmaceuticals, Inc. Today announced that patient enrollment has started in a Phase 2a, randomized, double-blind, placebo-controlled study to measure the efficacy and safety of ALV003 for use in the treating celiac disease. Adelman, M erectile dysfunction treatment .D. Related StoriesOne nights sleep deficiency and six months on high-fat diet could both impair insulin sensitivityConsuming high-fat diet can lead to anxiousness and depression, trigger measurable adjustments in the brainDiet lacking soluble fiber promotes irritation in the intestines, resulting in excess weight gainThe objective of the analysis is to measure the potential for patient benefit and gather safety data regarding do it again dosing with ALV003, as well as to evaluate potential endpoints for make use of in subsequent Phase 2b and 3 studies.